關於這一集
FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.
英語
美國
逐字稿 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
本 Podcast 中的其他單集
Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them?
John breaks down glutathione biolo…
For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides
Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily.
This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semagluti…
Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease.
But is a vial labeled "Follistatin-344" equivalent to the therapy used in thos…
Download The Peptide App at ThePeptide.App/Explained
For more information on research peptides check out PeptidesExplained.info/OfflinePeptides
A peptide…in a pill?
Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasi…
免責聲明: 本頁面嵌入的 Podcast 和封面圖片來自 John Garrett，歸其所有者所有，與 Listen Notes, Inc. 無關聯，也未獲得 Listen Notes, Inc. 背書。
